Cargando…
Long-Term Pulmonary Function in Duchenne Muscular Dystrophy: Comparison of Eteplirsen-Treated Patients to Natural History
BACKGROUND: Duchenne muscular dystrophy (DMD) is a rare, degenerative, X-linked genetic disease that results in progressive muscle loss and premature death, most commonly from respiratory or cardiac failure. DMD is primarily caused by whole exon deletions, resulting in a shift of the dystrophin mRNA...
Autores principales: | Kinane, T. Bernard, Mayer, Oscar H., Duda, Petra W., Lowes, Linda P., Moody, Stephanie L., Mendell, Jerry R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836407/ https://www.ncbi.nlm.nih.gov/pubmed/29278896 http://dx.doi.org/10.3233/JND-170272 |
Ejemplares similares
-
Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy
por: Khan, Navid, et al.
Publicado: (2019) -
Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls
por: Mendell, Jerry R., et al.
Publicado: (2021) -
Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy
por: Alfano, Lindsay N., et al.
Publicado: (2019) -
Eteplirsen in the treatment of Duchenne muscular dystrophy
por: Lim, Kenji Rowel Q, et al.
Publicado: (2017) -
FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2017)